# US 2013/0157347 A1 · Method of Analyzing Cardiovascular Disorders and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157347 A1
- Document ID: US20130157347A1
- Status: Published application
- Kind: A1
- Application number: 13/543,661
- Filed: 2012-07-06
- Published: 2013-06-20
- Earliest claimed: 2011-07-07
- Assignees: Veridex, LLC; Scripps Health
- Inventors: Eric Topol; Samir Damani; Mark Connelly; Galla Chandra Rao
- Web page: https://patentgrep.com/patent/US20130157347A1

## CPC

- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- G01N 15/1433: using image recognition
- G01N 33/5026: {on cell morphology}
- G01N 33/5064: {Endothelial cells}
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).

## Claims

### Claim 1

A system for analyzing a cardiovascular disorder in an individual in need thereof, comprising:
(a) a population of circulating endothelial cells (CEC) isolated from a blood sample obtained from the individual, wherein the blood sample comprises cells selected from CECs and circulating non-endothelial cells; and
(b) a microscope having sufficient magnifying power to visualize a morphological feature of a single CEC in the population of CECs;
wherein the morphological feature is selected from: cellular area, nuclear area, ratio of cellular area to nuclear area, cell shape, nuclei shape, number of nuclei, number of circulating endothelial cells, or a combination thereof.

### Claim 2 (depends on 1)

The system of claim 1, further comprising electronic memory for capturing and storing a magnified image of the population of CECs or a single CEC in the population of CECs.

### Claim 3 (depends on 1)

The system of claim 1, further comprising a computer-processing device, optionally connected to a computer network.

### Claim 4 (depends on 3)

The system of claim 3, further comprising a software module executed by the computer-processing device to analyze a morphological feature of the population of circulating endothelial cells (CEC)

### Claim 5 (depends on 3)

The system of claim 3, further comprising a software module executed by the computer-processing device to compare the morphological feature of the population of circulating endothelial cells (CEC) to a standard or control.

### Claim 6 (depends on 3)

The system of claim 3, further comprising a software module executed by the computer-processing device to determine concentration of the population of circulating endothelial cells isolated from the blood sample.

### Claim 7 (depends on 6)

The system of claim 6, further comprising a software module executed by the computer-processing device to compare the concentration of the population of circulating endothelial cells to the concentration of control or standard.

### Claim 8 (depends on 1)

The system of claim 1, further comprising a machine to isolate the population of circulating endothelial cells from the blood sample.

### Claim 9 (depends on 1)

The system of claim 1, further comprising a label that specifically binds to circulating endothelial cells, a label that does not bind to circulating endothelial cells, or a combination thereof.

### Claim 10 (depends on 1)

The system of claim 1, further comprising a label that specifically binds to CD146, a label that specifically binds to CD105, a label that specifically binds to CD45, a label that specifically binds to CD34, a label that specifically binds to CD31, a label that specifically binds to VEGF2, a label that specifically binds to CD144, a label that specifically binds to CD106, or a combination thereof.

### Claim 11 (depends on 1)

The system of claim 1, further comprising anti-CD146 antibodies, anti-CD105 antibodies, anti-CD45 antibodies, anti CD34 antibodies, anti-CD31 antibodies, anti-VEGF2 antibodies, anti-CD144 antibodies, anti-CD106 antibodies, or a combination thereof.

### Claim 12 (depends on 10)

The system of claim 10, wherein the antibodies are labeled.

### Claim 13 (depends on 10)

The system of claim 10, wherein the antibodies are labeled with a fluorescent moiety or a magnetic moiety.

### Claim 14 (depends on 3)

The system of claim 3, further comprising a software module executed by the computer-processing device to transmit an analysis of the morphological feature of the population of CECs to the individual or a medical professional treating the individual.

### Claim 15 (depends on 1)

The system of claim 1, further comprising a software module executed by the computer-processing device to transmit a diagnosis or prognosis to the individual or a medical professional treating the individual.

### Claim 16 (depends on 1)

The system of claim 1, wherein the cardiovascular disorder is selected from: plaque rupture, plaque erosion, ischemia of the heart, reperfusion injury to the heart, atherosclerosis, or a combination thereof.

### Claim 17 (depends on 1)

The system of claim 1, wherein the cardiovascular disorder is acute coronary syndrome.

### Claim 18 (depends on 1)

The system of claim 1, wherein the cardiovascular disorder is selected from: ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), unstable angina, or a combination thereof.

### Claim 19 (depends on 1)

The system of claim 1, wherein the cardiovascular disorder is ischemic stroke.

### Claim 20 (depends on 1)

The system of claim 1, wherein the cardiovascular disorder is atherosclerosis.

### Claim at position 21

-230. (canceled)
